The Lifestyle Drugs Market Is Currently Worth A Phenomenal $23bn
Assess the premium associated with different lifestyle drug markets and identify the potential for higher volume sales

/Pharmaceutical News Articles/ -- Research and Markets (http://www.researchandmarkets.com/reports/c7851) has announced the addition of 'The Lifestyle Drugs Outlook to 2008: Unlocking new value in well-being' to their offering

The lifestyle drugs market is currently worth a phenomenal $23bn. To boost its value pharmaceutical companies are actively searching for new lifestyle products and conditions. The Lifestyle Drugs Outlook to 2008: Unlocking new value in well-being, provides a timely market update, examining leading products and pipeline prospects in seven key lifestyle drug sectors, and is supported by forecasts to 2008. Today's R&D is influenced as much by commercial unmet needs as it is by clinical opportunities and chance. Pharmaceutical companies must react quickly to these needs if they are to reap greater financial returns. This report can help you to assess the premium associated with different lifestyle drug markets and identify the potential for higher volume sales. Armed with this information your company can formulate winning lifestyle drug development and marketing strategies, and secure a strong competitive position within this market.

Report Contents:

Chapter 1 The new premium pharmaceutical environment
Chapter 2 Depression
Chapter 3 Oral contraception
Chapter 4 Sexual dysfunction
Chapter 5 Smoking cessation
Chapter 6 Obesity
Chapter 7 Alopecia
Chapter 8 Skin aging



For more information visit http://www.researchandmarkets.com/reports/c7851

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980

Press Release Contact Information:

Patrick Good
Research and Markets
Press Officer
Voice: 00353 1 4151243
Fax: 00353 1 4100980